Approval of the Phase 1/2 open-label clinical trial in lupus nephritis by the Paul Ehrlich Institute in Germany follows KYV-101 Fast Track Designation by the U.S. Food and Drug Administration earlier this year KYV-101 is a novel, fully human CD19 CAR T-cell therapy designed for use in…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.